Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
4.580
-0.080 (-1.72%)
Mar 19, 2026, 4:00 PM EDT - Market closed
Opus Genetics Revenue
In the year 2025, Opus Genetics had annual revenue of $14.20M with 29.15% growth. Opus Genetics had revenue of $3.87M in the quarter ending December 31, 2025, a decrease of -10.16%.
Revenue (ttm)
$14.20M
Revenue Growth
+29.15%
P/S Ratio
22.95
Revenue / Employee
$788,667
Employees
18
Market Cap
325.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.20M | 3.20M | 29.15% |
| Dec 31, 2024 | 10.99M | -8.06M | -42.30% |
| Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
| Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
| Dec 31, 2021 | 589.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 75.00K | - | - |
| Dec 31, 2007 | 75.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 228.37M |
| Bicycle Therapeutics | 72.59M |
| Ovid Therapeutics | 7.25M |
| Armata Pharmaceuticals | 5.05M |
| AC Immune | 4.51M |
| Silence Therapeutics | 559.00K |
IRD News
- 9 days ago - Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update - GlobeNewsWire
- 16 days ago - Opus Genetics to Present at Upcoming Investor Conferences in March 2026 - GlobeNewsWire
- 20 days ago - Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting - GlobeNewsWire
- 22 days ago - Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewsWire
- 25 days ago - Opus Genetics: Asymmetric Upside With LCA5 And BEST1 - Seeking Alpha
- 4 weeks ago - Opus Genetics Announces $25 Million Private Placement - GlobeNewsWire
- 6 weeks ago - Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026 - GlobeNewsWire
- 7 weeks ago - Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa - GlobeNewsWire